Bibliography
- Wigley FM. Scleroderma (systemic sclerosis). In: Goldman L, Ausiello D, editors, Cecil Medicine. 23rd edition. Philadelphia: Saunders Elsevier; 2008. p.2032-41
- Valentini G. The assessment of the patient with systemic sclerosis. Autoimmun Rev 2003;2:370-6
- Le Roy EC, Black CM, Fleichmajer R, et al. Scleroderma (systemic sclerosis): classification, subset and pathogenesis. J Rheumatol 1988;15:894-8
- Medsger TA Jr. Classification, purpose. In: Clements PJ, Furst DE, editors, Systemic sclerosis. 2nd edition. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 17-28
- Furst DE, Clements PJ, Seibold JR. Treatment of systemic sclerosis by potentially disease-modifyng drugs. In: Clements PJ, Furst DE, editors, Systemic sclerosis. 2nd edition. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 351-63
- Mosca M, Bombardieri S. Assessing remission in systemic lupus erythematosus. Clin Exp Rheumatol 2006;24(Suppl 43):99-104
- Aletaha D, Smolen JS. Remission of rheumatoid arthritis: should we care about definitions Clin Exp Rheumatol 2006;24(Suppl 43):45-51
- Valentini G, Medsger TA Jr, Silman AJ, Bombardieri S. Conclusion and identification of the core set of variable to be used in clinical investigations. Clin Exp Rheum 2003;21(Suppl 3):47-8
- Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheum 2003;21(Suppl 3):39-41
- Medsger TA, Bombardieri S, Czirjak L, et al. Assessment of disease severity and prognosis. Clin Exp Rheum 2003;21(Suppl 3):42-6
- Khanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007;9:151-7
- Valentini G, Matucci Cerinic M. Disease-specific quality indicators, guideline and outcome measures in scleroderma. Clin Exp Rheumatol 2007; In press
- Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR/EUSTAR recommendations for the management ofsystemic sclerosis (SSc). Ann Rheum Dis 2007;25(Suppl 47):S159-62
- Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999;318:593-6
- van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-72
- Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8
- Apras S, Ertenli I, Ozbalkan Z, et al. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 2003;48:2256-61
- Valentini G, Paone C, La Montagna G, et al. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol 2006;35:35-8
- Paone C, Chiarolanza I, Cuomo G, et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1 year with low-dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 2007;25:613-6
- Nihtyanova SI, Brough GM, Black CM, Denton C. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis – a retrospective analysis. Rheumatology (Oxford) 2007;46:442-5
- Vanthuyne M, Blockmans D, Westhovens R, et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007;25:287-92
- Sfikakis PP, Gorgoulis VG, Katsiari CG, et al. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology 2008; [Epub ahead of print]
- Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66
- Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70
- Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-40
- Waxman AB. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. Vasc Health Risk Manag 2007;3:151-7
- Avouac J, Wippf J, Kahan A, Allanore Y. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a metaanalysis of randomised controlled trials. Ann Rheum Dis [Epub ahead of print]
- Le Roy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6
- Antoniu SA. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs 2006;15:823-8
- Ammar YA, Ismail MM, El-Sehrawi HM, et al. Novel pirfenidone analogues: synthesis of pyridin-2-ones for the treatment of pulmonary fibrosis. Arch Pharm (Weinheim) 2006;339:429-36
- Svegliati Baroni S, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76
- Kuwana M, Okazaki Y, Yasuoka H, et al. Defective vasculogenesis in systemic sclerosis. Lancet 2004;364:603-10
- Mayes MD, Trojanowska M. Genetic factors in scleroderma. Arthritis Res Ther 2007;9(Suppl 2):S5-11
- Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367:1683-91
- Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999;276:L311-8
- Nakazato H, Oku H, Yamane S, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level. Eur J Pharmacol 2002;446:177-85
- Soria A, Cario-André M, Lepreux S, et al. The effect of imatinib (Glivec) on scleroderma and normal fibroblasts: a preclinical study. Dermatology 2008;216:109-17
- Distler JH, Jüngel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22
- Riemekasten G, Heidecke H, Nather M, et al. Systemic sclerosis patients have activating antibodies targeting both endothelin receptor type A and angiotensin II type 1 receptor predicting worse prognosis. Ann Rheum Dis 2007;66(Suppl II):109
- Lafyatis R, Kissin E, Viger K, et al. Rituximab treatment for patients with diffuse cutaneous systemic sclerosis. A phase I study. Arthritis Rheum 2006;54(Suppl):S523-4
- Gu SY, Kong J, Cheema GS, et al. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008; [Epub ahead of print]
- Svegliati Baroni S, Cancello R, Sambo P, et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 2005;280:36474-82
- Servettaz A, Guilpain P, Goulvestre C, et al. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis 2007;66:1202-9
- Ferri C, Giuggioli D, Sebastiani M, Colaci M. Treatment of severe scleroderma skin ulcers with recombinant human erythropoietin. Clin Exp Dermatol 2007;32:287-90
- Fukumoto Y, Tawara S, Shimokawa H. Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors. Tohoku J Exp Med 2007;211:309-20
- Valentini G, Black C. Systemic sclerosis. Best Pract Res Clin Rheumatol 2002;16:807-16
- Seibold JR, Furst DE, Clements PJ. Why everything (or nothing) seems to work in the treatment of scleroderma. J Rheumatol 1992;19:673-6
- Merkel PA, Clements PJ, Reveille JD, et al. OMERACT 6. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003;30:1630-47
- Khanna D, Furst DE, Hays RD, et al. Minimally important difference in diffuse systemic sclerosis.results from the d-penicillamine study. Ann Rheum Dis 2006;65:1325-9
- Khanna D, Lovell DE, Giannini E, et al. Development of provisional core set of response measures for clinical trials of systemic sclerosis [abstract 2162]. Arthritis Rheum 2007;56(Suppl):S823
- Kahan A, Amor B, Menkes CJ, Strauch G. Recombinant interferon-gamma in the treatment of systemic sclerosis. Am J Med 1989;87:273-7
- Black CM, Silman AJ, Herrick AI, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:299-305
- Seibold JR, Korn JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;132:871-9
- Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33